News Digging > News > Novo-backed startup touts a PhII win for atrial fibrillation program
Novo-backed startup touts a PhII win for atrial fibrillation program
Novo-backed startup touts a PhII win for atrial fibrillation program,Denmark-based biotech Acesion Pharma is tackling atrial fibrillation (AF), the most common cardiac arrhythmia, with AP30663, its SK ion channel inhibitor that is being developed to bring the heart back to a normal, healthy rhythm. Acesion released data from its Phase II trial, conducted in hospitals in Hungary and Denmark

Novo-backed startup touts a PhII win for atrial fibrillation program

Denmark-based biotech Acesion Pharma is tackling atrial fibrillation (AF), the most common cardiac arrhythmia, with AP30663, its SK ion channel inhibitor that is being developed to bring the heart back to a normal, healthy rhythm. Acesion released data from its Phase II trial, conducted in hospitals in Hungary and Denmark